Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024
2024
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service,
· University of Rochester,
· University of Cincinnati,
· Cincinnati Children's Hospital Medical Center,
· Vanderbilt University,
· Texas Children's Hospital,
· Baylor College of Medicine,
· University of Washington,
· University of Pittsburgh,
· Children's Mercy Kansas City
This study looks at the impact of respiratory syncytial virus (RSV) in young children during the 2023-2024 season. It describes how two new RSV prevention …
Ask aRCie
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
2024
· Centers for Disease Control and Prevention (CDC),
· Vanderbilt University,
· Seattle Children's Hospital,
· Baylor College of Medicine,
· University of Rochester
This study examines the effectiveness of nirsevimab, a monoclonal antibody, in preventing RSV-related hospitalizations in infants during their first RSV season. Conducted from October 2023 …
RSV Prevention - Breakthroughs and Challenges
2023
· Vanderbilt University
This editorial discusses recent advances and ongoing challenges in preventing RSV, a common respiratory virus. The article highlights new methods being developed to protect people, …